Salvi Nicola, Dalvit Claudio, Frances Oriane, Vallée François, Rak Alexey
Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France.
Lavis, Trento, Italy.
Methods Mol Biol. 2025;2905:193-206. doi: 10.1007/978-1-0716-4418-8_13.
In drug discovery, precise target validation and ligandability assessment are pivotal processes. This article introduces an advanced protocol employing fluorine-19 (F) NMR spectroscopy for fragment-based screening (FBS). This innovative methodology distinguishes fragment hits and elucidates their binding interactions, even within millimolar concentration ranges. Leveraging the distinctive advantages of F NMR, such as high signal dispersion, background-free spectra, and heightened sensitivity to protein binding, this technique emerges as a potent tool for early-stage drug discovery. The demonstrated application of this protocol in target validation, with a specific emphasis on ligandability assessment, provides a means to gauge the inherent challenges associated with a target right from the outset of a project.
在药物研发中,精确的靶点验证和可配体性评估是关键步骤。本文介绍了一种采用氟-19(F)核磁共振光谱进行基于片段筛选(FBS)的先进方案。这种创新方法能够区分片段命中物并阐明其结合相互作用,即使在毫摩尔浓度范围内也是如此。利用F核磁共振的独特优势,如高信号分散性、无背景光谱以及对蛋白质结合的高灵敏度,该技术成为早期药物研发的有力工具。该方案在靶点验证中的应用,特别是在可配体性评估方面的应用,提供了一种从项目一开始就衡量与靶点相关固有挑战的方法。